Clinical Trial Details

A Phase 3 Study of Selumetinib (NSC# 748727, IND# 77782) or Selumetinib in Combination with Vinblastine for non-NF1, non-TSC Patients with Recurrent or Progressive Low-Grade Gliomas (LGGs) Lacking BRAFV600E or IDH1 Mutations

Categories (click each to see list of all clinical trials associated with that category): Pediatric (PEDONC)

Current Status: Open

Phase: III (Cancer Control)

Principal Investigator: Beck, Jill

Contact Information:
Angie Boettner
aboettner@unmc.edu

Eligibility: https://clinicaltrials.gov/study/NCT04576117?term=NCT04576117&rank=1

Summary
PRIMARY OBJECTIVES: I. To determine the maximum tolerated dose/recommended phase 2 dose (MTD/RP2D) of selumetinib sulfate (selumetinib) + vinblastine sulfate (vinblastine) for children with progressive or recurrent low-grade gliomas (LGGs). II. To determine if selumetinib + vinblastine will lead to improved event-free survival (EFS) outcome compared with selumetinib alone for children with progressive or recurrent LGGs.